Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Danica, and I will be your conference operator today.
Exact Sciences Corp (EXAS)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 3,267,648 | $225,663,760 | -46% | 1.56% |
| 2. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,361,415 | $94,019,320 | +21% | 1.99% |
| 3. | Fisher Asset Management Ken Fisher | 157,757 | $10,894,723 | +4% | 0% |
| 4. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 51,711 | $3,571,162 | +1% | 1.48% |
| 5. | McKinley Capital Management Robert B. Gillam | 36,070 | $2,490,994 | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.71 | 2,500 | Director | 60,858 | 2017-08-17 | Filing | |
| $13.84 | 10,000 | Director | 136,379 | 2016-12-14 | Filing | |
| $18.10 | 5,000 | Director | 121,247 | 2016-09-01 | Filing | |
| $17.93 | 3,380 | Director | 105,927 | 2016-08-03 | Filing | |
| $5.38 | 3,775 | Director | 91,000 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $60.15 | 67 | 44,644 | 2024-05-01 | Filing | ||
| $60.15 | 136 | 47,042 | 2024-05-01 | Filing | ||
| $60.15 | 30 | 9,866 | 2024-05-01 | Filing | ||
| $60.15 | 136 | 11,795 | 2024-05-01 | Filing | ||
| $60.15 | 110 | 13,279 | 2024-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,559,751 | $1,299,070,379 | 0.02% | |
| 2. | 16,690,808 | $1,234,786,033 | 0.13% | |
| 3. | 11,053,013 | $817,701,874 | 0.02% | |
| 4. | 10,280,814 | $760,574,619 | 0.14% | |
| 5. | 7,468,145 | $552,493,367 | 0.09% |
News See All
Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.
Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.
Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript
Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.53.
Top 5 CRISPR Stocks To Invest In
Exact Sciences Corporation (NASDAQ:EXAS) specializes in cancer screening and diagnostic test products, operating both in the United States and internationally.
5 Most Promising Gene Editing Stocks According to Hedge Funds
In this piece, we will take a look at the five most promising gene editing stocks according to hedge funds.
5 Most Promising Healthcare Stocks According to Analysts
In this article, we discuss the 5 most promising healthcare stocks according to analysts.
Ark Invest Stock Portfolio: 16 Biggest Positions
In this article, we discuss the 16 biggest positions in the ARK Invest portfolio.
Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here.
15 Stocks with Consistent Growth
Growth companies and companies working on disruptive technologies were hit hardest by the market conditions as the cost of capital rose significantly in a short period of time.
Billionaire Hedge Funds
